McKesson Corporation (MCK), a global healthcare services and information technology company, posted a significant financial improvement in its Q3 2026 results. The company's stock price has experienced significant increases due to raised profit forecasts. MCK's stock performance, driven by favourable oncology and GLP-1 momentum, is being hailed by *Jim Cramer* as a company that consistently flies when it reports. The corporation's earnings and revenues exceeded predictions.
Benefiting and contributing to the recent successes are strong investment in technology and a portfolio focus in oncology. The corporation's strategic focus following the *divestiture of Norwegian operations* further contributed to the strength of McKesson. Despite this, the company saw a 5.2% decline in their stock since their last earnings report.
Analysts continue to rate MCK favourably with several firms including *TD Cowen, Wells Fargo, and Baird* raising their price targets. The shares are considered undervalued by 42% according to some assessments. Nevertheless, McKesson's financial stability and performance over the past few years have solidified its standing as a favourite amongst institutional investors, with about 90% backing from such firms.
Mckesson Corporation MCK News Analytics from Wed, 25 Jun 2025 00:08:50 GMT to Fri, 06 Feb 2026 16:21:40 GMT -
Rating 8
- Innovation 3
- Information 7
- Rumor -6
